ClinicalTrials.gg
CompletedNCT03233308Updated Aug 6, 2019Results posted

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

A Phase 2 interventional study of Netarsudil Ophthalmic Solution 0.02% and Placebo Comparator in Primary Open Angle Glaucoma or Ocular Hypertension, sponsored by Aerie Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-06.

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Enrollment
14th of 17
20 · median 85
Started
2017
with 1 other
Phase 2
6 of 17
none open now
Registered
7th of 17
by date
Lead sponsor
11 of 17
Aerie Pharmaceuticals

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 14th largest by enrollment, is one of 2 that started in 2017, is one of 6 in phase 2, and was the 7th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo

Read the detailed description

Trabecular outflow facility is a measure of aqueous humor dynamics; effect of netarsudil on this parameter as well as on intraocular pressure and episcleral venous pressure was evaluated in this study. Netarsudil treatment was given in one eye and placebo given in contralateral eye for 7 consecutive days.

03

Conditions studied

  • Primary Open Angle Glaucoma or Ocular Hypertension

Keywords

  • Aqueous Humor Dynamics
  • Trabecular Outflow
  • Netarsudil
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be 18 years of age or older
  2. Diagnosis of open primary angle glaucoma(POAG) or ocular hypertension (OHT) in both eyes
  3. Unmedicated intraocular pressure (IOP) >20 mmHg and \< 30 mmHg in both eyes at first qualification visit
  4. Best corrected visual acuity (BCVA) equivalent to 20/200 Snellen or better
  5. Able to give and follow study instructions

Exclusion criteria

Exclusion Criteria:

Ophthalmic:

  1. ocular disease
  2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles
  3. Intraocular pressure ≥30 mmHg in either eye
  4. A difference in IOP between eyes >4mmHg at qualification visit
  5. Use of more than two ocular hypotensive medications within 30 days of screening
  6. Known to any component of the formulation
  7. Previous glaucoma surgery or refractive surgery
  8. Keratorefractive surgery in either eye
  9. Report of ocular injury in either eye within the six months prior to screening or ocular or non-refractive surgery within 3 months prior to screening
  10. Recent or current ocular infection or inflammation in either eye
  11. Use of ocular medication in either eye of any kind within 30 days of screening
  12. Mean central corneal thickness greater than 620 μm in either eye
  13. Any abnormality preventing reliable applanation tonometry of either eye
  14. Lack of suitable episcleral vein prior to performing Episcleral Venus Pressure (EVP) measurement (applicable to 1 site only)

    Systemic:

  15. Clinically significant abnormalities within 6 weeks prior to screening
  16. Clinically significant systemic disease
  17. Participation in any study within 60 days prior to screening
  18. Use of systemic medication that could have an effect on intraocular pressure within 30 days prior to screening
  19. Women of who were pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Netarsudil Ophthalmic Solution 0.02%

    Netarsudil Ophthalmic Solution 0.02% was administered in one eye and Placebo comparator in contralateral eye

    Drug: Netarsudil Ophthalmic Solution 0.02% · Other: Placebo Comparator

  • Placebo comparator
    Placebo Comparator

    Placebo comparator administered in one eye and Netarsudil Ophthalmic Solution 0.02% in contralateral eye

    Drug: Netarsudil Ophthalmic Solution 0.02% · Other: Placebo Comparator

Interventions

  • 1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye

  • OtherPlacebo Comparator

    1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Mean Diurnal Trabecular Outflow Facility

    Mean diurnal change from baseline in trabecular (tonographic) outflow facility.

    Time frame: Study treatment was administered for 7 days, and outcome measures collected on Day 8

  2. Mean Percent Change From Baseline in the Mean Diurnal Trabecular Outflow Facility.

    Mean diurnal change from baseline in trabecular (tonographic) outflow facility.

    Time frame: Study treatment was administered for 7 days, and outcome measures collected on Day 8

Secondary outcomes

  1. Mean Change From Baseline in Episcleral Venous Pressure (EVP) and in Intraocular Pressure (IOP)

    Mean diurnal change from baseline in mean diurnal IOP measured using a Pneumatonometer and mean diurnal EVP using a custom-modified slit-lamp mounted venomanometer. (EVP conducted at a single site in only 9 participants)

    Time frame: Study treatment was administered for 7 days, and outcome measures collected on Day 8

  2. Mean Percent Change From Baseline in Episcleral Venous Pressure (EVP) and in Intraocular Pressure (IOP)

    Mean diurnal change from baseline in mean diurnal IOP measured using a Pneumatonometer and mean diurnal EVP using a custom-modified slit-lamp mounted venomanometer. (EVP conducted at a single site in only 9 participants)

    Time frame: Study treatment was administered for 7 days, and outcome measures collected on Day 8

07

Results

Posted Jun 11, 2019

Participant flow

Participant flow — Overall Study
MilestoneAll Randomized Patients
Started20
Completed18
Not completed2
Withdrew: Adverse event1
Withdrew: Protocol violation1

Outcome measures

PrimaryMean Change From Baseline in the Mean Diurnal Trabecular Outflow Facility

Mean diurnal change from baseline in trabecular (tonographic) outflow facility.

Time frame:
Study treatment was administered for 7 days, and outcome measures collected on Day 8
Reported as:
Mean · mcl/min/mmHg
Mean Change From Baseline in the Mean Diurnal Trabecular Outflow Facility
mcl/min/mmHgNetarsudil Ophthalmic Solution 0.02%Placebo Comparator
Mean Change From Baseline in the Mean Diurnal Trabecular Outflow Facility0.039 ± 0.04010.007 ± 0.0275
Statistical analysis
  • Netarsudil Ophthalmic Solution 0.02% · t-test, 1 sided · p = 0.0010
PrimaryMean Percent Change From Baseline in the Mean Diurnal Trabecular Outflow Facility.

Mean diurnal change from baseline in trabecular (tonographic) outflow facility.

Time frame:
Study treatment was administered for 7 days, and outcome measures collected on Day 8
Reported as:
Mean · percentage change
Mean Percent Change From Baseline in the Mean Diurnal Trabecular Outflow Facility.
percentage changeNetarsudil Ophthalmic Solution 0.02%Placebo Comparator
Mean Percent Change From Baseline in the Mean Diurnal Trabecular Outflow Facility.34.589 ± 34.59359.597 ± 25.6334
Statistical analysis
  • Netarsudil Ophthalmic Solution 0.02% · t-test, 1 sided · p = 0.0003
SecondaryMean Change From Baseline in Episcleral Venous Pressure (EVP) and in Intraocular Pressure (IOP)

Mean diurnal change from baseline in mean diurnal IOP measured using a Pneumatonometer and mean diurnal EVP using a custom-modified slit-lamp mounted venomanometer. (EVP conducted at a single site in only 9 participants)

Time frame:
Study treatment was administered for 7 days, and outcome measures collected on Day 8
Reported as:
Mean · mmHg
Mean Change From Baseline in Episcleral Venous Pressure (EVP) and in Intraocular Pressure (IOP)
mmHgNetarsudil Ophthalmic Solution 0.02%Placebo Comparator
Diurnal EVP (delta vs.baseline)-0.787 ± 0.83720.103 ± 0.7094
Diurnal IOP (delta vs.baseline)-4.521 ± 1.5842-0.979 ± 1.6009
Statistical analysis
  • Netarsudil Ophthalmic Solution 0.02% · t-test, 1 sided · p = 0.0687
  • Netarsudil Ophthalmic Solution 0.02% · t-test, 1 sided · p = <0.0001
SecondaryMean Percent Change From Baseline in Episcleral Venous Pressure (EVP) and in Intraocular Pressure (IOP)

Mean diurnal change from baseline in mean diurnal IOP measured using a Pneumatonometer and mean diurnal EVP using a custom-modified slit-lamp mounted venomanometer. (EVP conducted at a single site in only 9 participants)

Time frame:
Study treatment was administered for 7 days, and outcome measures collected on Day 8
Reported as:
Mean · percentage change
Mean Percent Change From Baseline in Episcleral Venous Pressure (EVP) and in Intraocular Pressure (IOP)
percentage changeNetarsudil Ophthalmic Solution 0.02%Placebo Comparator
Percent change from baseline (EVP)-9.465 ± 9.50443.103 ± 7.7322
Percent change from baseline (IOP)-19.568 ± 6.0713-4.227 ± 6.9699
Statistical analysis
  • Netarsudil Ophthalmic Solution 0.02% · t-test, 1 sided · p = 0.0087
  • Netarsudil Ophthalmic Solution 0.02% · t-test, 1 sided · p = <0.0001

Adverse events

Collected over 7 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Netarsudil Ophthalmic Solution 0.02%0/20 (0%)0/20 (0%)13/20 (65%)
Placebo Comparator0/20 (0%)0/20 (0%)0/20 (0%)
Most frequent other events
Most frequent other events
EventNetarsudil Ophthalmic Solution 0.02%Placebo Comparator
Conjunctival HyperaemiaEye disorders13/200/20
Eye IrritationEye disorders3/200/20
Vision BlurredEye disorders2/200/20
Eye SwellingEye disorders1/200/20
PhotophobiaEye disorders1/200/20

Baseline characteristics

Modified intent-to-treat (mITT) population

Age, Categorical
Age, Categorical(Participants)All Randomized Patients
<=18 years0
Between 18 and 65 years9
>=65 years11
Age, Continuous
Age, Continuous(years)All Randomized Patients
Mean63 ± 12.53
Sex: Female, Male
Sex: Female, Male(Participants)All Randomized Patients
Female14
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Randomized Patients
Hispanic or Latino1
Not Hispanic or Latino19
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Randomized Patients
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American5
White14
More than one race0
Unknown or Not Reported0
08

Study locations

2 sites
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Duke Eye Center
    Durham, North Carolina 27710, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Apr 2018, 5 months.

Results were first posted in Jun 2019, 1 year 1 month after primary completion.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2017
First posted
Jul 28, 2017
StartActual
Oct 20, 2017
Primary completionActual
Apr 19, 2018
CompletionActual
Apr 19, 2018
Results first posted
Jun 11, 2019
Last update
Aug 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03233308
Responsible party
Sponsor
First posted
Jul 28, 2017
Start date
Oct 20, 2017
Primary completion
Apr 19, 2018
Completion
Apr 19, 2018
Results posted
Jun 11, 2019
Last update
Aug 6, 2019

Study contacts

Nancy Ramirez-Davis
study director · Aerie Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion